Combination Therapy and Appropriate Dosing to Target KRAS in Colorectal Cancer

In this issue of the Journal, Fakih et al.1 report the results from CodeBreaK 300, a phase 3 trial of the selective Kirsten rat sarcoma viral oncogene homologue (KRAS) glycine-to-cysteine mutation at codon 12 (KRAS G12C) inhibitor sotorasib in combination with the epidermal growth factor receptor (EGFR) inhibitor panitumumab in patients with metastatic colorectal cancer with KRAS G12C mutation. In this trial, two investigational groups — one that received full-dose sotorasib (960 mg once daily) in combination with panitumumab and one that received lower-dose sotorasib (240 mg once daily) in combination with panitumumab — were compared with a group that . . .